UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171-210

2019

Volltextzugriff (PDF)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Annals of oncology, 2020-02, Vol.31 (2), p.191-201

2020

Volltextzugriff (PDF)

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Annals of oncology, 2024-09, Vol.35 (9), p.805-816

2024

Volltextzugriff (PDF)

Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country

Journal of cancer education, 2022-02, Vol.37 (1), p.169-178

2022

Volltextzugriff (PDF)

1023 Prostate cancer in multi-ethnic Asian men

European journal of cancer (1990), 2015-09, Vol.51, p.S152-S153

2015

Volltextzugriff (PDF)

100 Continuous hyperfractionated accelerated radiotherapy (CHART) for patients with inoperable non-small cell lung Cancer (NSCLC): 10 year experience of the Exeter Oncology Centre

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S35-S35

2011

Volltextzugriff (PDF)

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

The New England journal of medicine, 2023-11, Vol.389 (22), p.2039-2051

2023

Volltextzugriff (PDF)

354P Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)

Annals of oncology, 2020-11, Vol.31, p.S1377-S1377

2020

Volltextzugriff (PDF)

147 Sequential chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC): experience from nine UK centres

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S54-S54

2014

Volltextzugriff (PDF)

289P The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre

Annals of oncology, 2016-12, Vol.27, p.ix91-ix91

2016

Volltextzugriff (PDF)

289P The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)

Annals of oncology, 2023-11, Vol.34, p.S1486

2023

Volltextzugriff (PDF)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

Annals of oncology, 2023-11, Vol.34, p.S1661

2023

Volltextzugriff (PDF)

Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib

Annals of oncology, 2019-11, Vol.30, p.ix167

2019

Volltextzugriff (PDF)

Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma

Annals of oncology, 2019-11, Vol.30, p.ix164

2019

Volltextzugriff (PDF)

EP1.14-17 Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S1038-S1038

2019

Volltextzugriff (PDF)

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

Annals of oncology, 2023-10, Vol.34, p.S1306-S1306

2023

Volltextzugriff (PDF)

Quantification of plasma epstein-barr virus dna in patients with nasopharyngeal carcinoma: Preliminary results of a prospective study

Radiotherapy and oncology, 2007-02, Vol.82, p.S26-S27

2007

Volltextzugriff (PDF)

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S616-S617

2018

Volltextzugriff (PDF)

P3.13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S981-S982

2018

Volltextzugriff (PDF)

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S998-S999

2018

Volltextzugriff (PDF)

P2.14-47 Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S848-S848

2019

Volltextzugriff (PDF)

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor -Tyrosine Kinase Inhibitors

Cancer management and research, 2020-01, Vol.12, p.5439-5450

2020

Volltextzugriff (PDF)

The Electrical Characteristics of Aluminium Doped Zinc Oxide Thin Film for Humidity Sensor Applications

Advances in materials science and engineering, 2011-01, Vol.2011 (2011), p.1-5

2011

Volltextzugriff (PDF)

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171

2019

Volltextzugriff (PDF)

1 – 25 von 491

Suche als RSS-Feed

Aktive Filter

KollektioneBooks on EBSCOhost

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(333)
Mit Volltextzugriff
(308)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Life Sciences & Biomedicine
(103)
Humans
(79)
Gastroenterology And Hepatology
(28)
Male
(28)
Caco-2 Cells
(27)
Animals
(24)
Gastroenterology & Hepatology
(24)
Physiology
(24)
Technology
(23)
Science & Technology - Other Topics
(21)
Intestinal Mucosa - Metabolism
(19)
Mice
(19)
Physical Sciences
(19)
Biological And Medical Sciences
(16)
Diarrhea
(16)
Oncology
(16)
Cell Line
(15)
Female
(15)
Inflammation
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(20)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country

1023 Prostate cancer in multi-ethnic Asian men

100 Continuous hyperfractionated accelerated radiotherapy (CHART) for patients with inoperable non-small cell lung Cancer (NSCLC): 10 year experience of the Exeter Oncology Centre

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

354P Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)

147 Sequential chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC): experience from nine UK centres

289P The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre

289P The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre

LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib

Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma

EP1.14-17 Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

Quantification of plasma epstein-barr virus dna in patients with nasopharyngeal carcinoma: Preliminary results of a prospective study

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

P3.13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

P2.14-47 Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor -Tyrosine Kinase Inhibitors

The Electrical Characteristics of Aluminium Doped Zinc Oxide Thin Film for Humidity Sensor Applications

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Aktive Filter

Suchergebnisse filtern